Definitions of Stage D heart failure and outcomes among outpatients with heart failure and reduced ejection fraction

Jeffrey S Hedley1, Ayman Samman-Tahhan2, Andrew A McCue3

  • 1Division of Cardiology, Cleveland Clinic, Cleveland, OH, United States of America.

Insights

Defining advanced heart failure (Stage D) is crucial. INTERMACS profiles offer a practical method for identifying Stage D heart failure (HF) in outpatients, outperforming other criteria in predicting outcomes.

Area of Science:

  • Cardiology
  • Heart Failure Research
  • Clinical Outcomes

Background:

  • A clear, operational definition for Stage D heart failure (HF) is currently absent.
  • This study addresses the need for a consensus definition in clinical practice.

Purpose of the Study:

  • To evaluate and compare three different definitions for Stage D heart failure (HF) in outpatients with reduced ejection fraction.
  • To determine which definition best predicts mortality and other adverse outcomes.

Main Methods:

  • 512 outpatients with systolic HF (ejection fraction ≤40%) were assessed.
  • Three definitions were applied: physician designation, INTERMACS profiles (2-6), and ESC-HFA criteria.
  • Patient outcomes, including mortality and hospitalization, were tracked over a median of 3.1 years.

Main Results:

  • Physician designation, INTERMACS profiles, and ESC-HFA criteria identified 12.5%, 18.2%, and 13.1% of patients as Stage D, respectively, with modest agreement.
  • The INTERMACS-based definition showed the best prognostic separation for 3-year mortality (HR 3.28) and hospitalization risk.
  • Physician designation (HR 3.17) and ESC-HFA criteria (HR 2.02) also predicted outcomes, but less effectively than INTERMACS profiles.

Conclusions:

  • INTERMACS profiles provide a practical and effective tool for identifying Stage D HF in ambulatory patients with systolic dysfunction.
  • The European Society of Cardiology Heart Failure Association (ESC-HFA) criteria demonstrated limited prognostic value in this cohort.
Abstract

Related Concept Videos

Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
964
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
3.8K
Heart Failure I: Introduction01:27

Heart Failure I: Introduction

Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
903
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
348
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
987
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
330